secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-07-01T20:10:23+00:00
Accession:  0001193125-26-292547
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates ASCO 2026 data; VMT-α-NET shows deepening responses in NETs
--------------------------------------------------------------------------------

- VMT-α-NET (212Pb for SSTR2+ NETs) shows best response deepens over time; durable disease control across doses; stable renal function in 68 patients.
- VMT01 (212Pb for MC1R+ melanoma) shows preliminary anti-tumor activity at 3.0 mCi dose; well-tolerated with TEAEs in ≥10% of patients.
- PSV359 (212Pb targeting FAP-ɑ) enters Phase 1/2a for advanced solid tumors with improved tumor retention.
- Pipeline also includes CCK2R81 for medullary thyroid cancer and combination with immune checkpoint inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526292547/0001193125-26-292547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526292547/catx-20260701.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-292547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer